{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=methyldopa", "query": { "intervention": "methyldopa" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 37, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=methyldopa&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T12:45:59.875Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01399905", "title": "High and Low Dose Carbidopa Treatment of Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "carbidopa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "35 Years to 85 Years" }, "enrollment_count": 14, "start_date": "2009-03", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2020-01-09", "last_synced_at": "2026-09-03T12:45:59.875Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01399905" }, { "nct_id": "NCT03761030", "title": "L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder", "Dysthymia", "Depression" ], "interventions": [ { "name": "L-DOPA", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 51, "start_date": "2019-01-09", "completion_date": "2021-09-08", "has_results": true, "last_update_posted_date": "2023-05-22", "last_synced_at": "2026-09-03T12:45:59.875Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03761030" }, { "nct_id": "NCT00914602", "title": "An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Sinemet 25-100 Oral Tablet", "type": "DRUG" }, { "name": "XP21279", "type": "DRUG" }, { "name": "Carbidopa Pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XenoPort, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "30 Years to 75 Years" }, "enrollment_count": 14, "start_date": "2009-05", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-09-03T12:45:59.875Z", "location_count": 2, "location_summary": "Peoria, Arizona • Bingham Farms, Michigan", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Bingham Farms", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00914602" }, { "nct_id": "NCT00223717", "title": "Treatment of Supine Hypertension in Autonomic Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Clonidine", "type": "DRUG" }, { "name": "Nitroglycerin transdermal", "type": "DRUG" }, { "name": "Dipyridamole/ Aspirin (Aggrenox)", "type": "DRUG" }, { "name": "Desmopressin (DDAVP)", "type": "DRUG" }, { "name": "Sildenafil", "type": "DRUG" }, { "name": "Nifedipine", "type": "DRUG" }, { "name": "Hydralazine", "type": "DRUG" }, { "name": "Hydrochlorothiazide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Bosentan", "type": "DRUG" }, { "name": "Diltiazem", "type": "DRUG" }, { "name": "Eplerenone", "type": "DRUG" }, { "name": "guanfacine", "type": "DRUG" }, { "name": "L-arginine", "type": "DIETARY_SUPPLEMENT" }, { "name": "captopril", "type": "DRUG" }, { "name": "carbidopa", "type": "DRUG" }, { "name": "losartan", "type": "DRUG" }, { "name": "metoprolol tartrate", "type": "DRUG" }, { "name": "nebivolol hydrochloride", "type": "DRUG" }, { "name": "prazosin hydrochloride", "type": "DRUG" }, { "name": "tamsulosin hydrochloride", "type": "DRUG" }, { "name": "Head-up tilt.", "type": "OTHER" }, { "name": "aliskiren", "type": "DRUG" }, { "name": "Local heat stress", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 152, "start_date": "2001-01", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-10-13", "last_synced_at": "2026-09-03T12:45:59.875Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00223717" }, { "nct_id": "NCT02633007", "title": "A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "CVT-301 (levodopa inhalation powder)", "type": "DRUG" }, { "name": "Carbidopa", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Acorda Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2015-12", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-13", "last_synced_at": "2026-09-03T12:45:59.875Z", "location_count": 3, "location_summary": "Daytona Beach, Florida • North Dartmouth, Massachusetts • Dallas, Texas", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "North Dartmouth", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02633007" }, { "nct_id": "NCT04325503", "title": "Neurobiological Drivers of Mobility Resilience: The Dopaminergic System", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Parkinsonian Signs in Older Persons" ], "interventions": [ { "name": "carbidopa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 14, "start_date": "2021-02-08", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2024-04-04", "last_synced_at": "2026-09-03T12:45:59.875Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04325503" }, { "nct_id": "NCT01770145", "title": "Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinson's Disease", "Motor Symptoms", "Akinesia", "Hypomobility", "Delayed Levodopa Onset" ], "interventions": [ { "name": "APOKYN", "type": "DRUG" }, { "name": "L-dopa", "type": "DRUG" }, { "name": "Trimethobenzamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2012-12", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-09-03T12:45:59.875Z", "location_count": 12, "location_summary": "Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Reseda", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01770145" }, { "nct_id": "NCT04625595", "title": "Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type1 Diabetes" ], "interventions": [ { "name": "350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule", "type": "DRUG" }, { "name": "700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule", "type": "DRUG" }, { "name": "1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule", "type": "DRUG" }, { "name": "1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunomolecular Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 30, "start_date": "2020-11-09", "completion_date": "2021-07-31", "has_results": false, "last_update_posted_date": "2021-08-25", "last_synced_at": "2026-09-03T12:45:59.875Z", "location_count": 3, "location_summary": "Chula Vista, California • Aurora, Colorado • Renton, Washington", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04625595" }, { "nct_id": "NCT04520178", "title": "Effects of 5HTP on the Injured Human Spinal Cord", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Spinal Cord Injuries" ], "interventions": [ { "name": "5-Hydroxytryptophan 100 MG", "type": "DRUG" }, { "name": "5-Hydroxytryptophan", "type": "DRUG" }, { "name": "Carbidopa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alberta", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2020-07-01", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-09-03T12:45:59.875Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04520178" }, { "nct_id": "NCT04467931", "title": "ACEI or ARB and COVID-19 Severity and Mortality in US Veterans", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hypertension", "COVID" ], "interventions": [ { "name": "ACEI/ARB", "type": "DRUG" }, { "name": "Non-ACEI/ARB", "type": "DRUG" }, { "name": "ACEI", "type": "DRUG" }, { "name": "ARB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22213, "start_date": "2020-01-19", "completion_date": "2020-12-31", "has_results": false, "last_update_posted_date": "2021-04-28", "last_synced_at": "2026-09-03T12:45:59.875Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04467931" } ] }